



HUMAN ARYL HYDROCARBON RECEPTOR (AhR) ACTIVATION ASSAY SYSTEM

Technical Manual for Human AhR activation in 384-Well Format Assay
Catalog# 1A2-DRE-384-001 and 1A2-DRE 384-002

Puracyp, Inc.
5900 Sea Lion Place
Suite 130
Carlsbad, CA 92010
760-929-9508
Fax: 760-929-9834
www.puracyp.com

IMPORTANT NOTE: BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE TERMS OF THE LIMITED USE DISCLOSURES AND STATEMENTS GIVEN IN SECTION V OF THE ACCOMPANYING LITERATURE

HUMAN AhR NUCLEAR RECEPTOR ACTIVATION ASSAY, WITH ASSESSMENT OF CELL VIABILITY AND CYP1A2 SUBSTRATE METABOLISM IN A 384-WELL FORMAT

This technical manual is available in its most current version at: www.puracyp.com. Please contact Puracyp if you have questions concerning the use of the assay system. 760-929-9508 ext. 103 or 113; Email: support@puracyp.com

I.	Description	3
II.	Product Components & Storage Conditions	4
III.	Materials to be Supplied by the User	5
IV.	Assay Procedure	7
	CELL RECEIPT	7
	DAY 1	7
	DAY 3 Receptor Activation	8
	DAY 3 P450 Metabolism and Receptor Activation	9
	QUANTITATION OF RECEPTOR ACTIVATION	10
	TROUBLESHOOTING GUIDE	13
V.	Limited Use Disclosures and Disclaimer	16
VI.	References	18
	APPENDIX 1: Positive Control Dilution Scheme	19
	APPENDIX 2: Test Compound Dilution Scheme	20
	APPENDIX 3: Quick Reference Sheet	21
	APPENDIX 4: Quick Reference Sheet Including P450 Metabolism	22

I. DESCRIPTION

Puracyp's nuclear receptor activation kits are all-inclusive cell-based assay systems. The kits incorporate mycoplasma-free, stably-transfected cells derived from hepatoma cell lines that have been treated with a cell-arrest agent to prevent further proliferation. Exposure to the cell-arrest agent ensures that the cells in the kits can only be used for a single 384-well assay. The kits also include a cell culture-ready assay plate, optimized cell culture medium, cell dosing medium, a positive control specific for the nuclear receptor, CellTiter-Fluor™ for determining cell viability, luciferase detection reagents and, if so ordered, a P450-Glo™ substrate for assessing induction of CYP450 enzyme activity. The primary application of these assay kits is to identify agents with the ability to activate PXR and/or AhR, thereby inducing drug-metabolizing enzymes and ABC transporters.

Puracyp's *Human AhR Activation Assay System* utilizes 1A2-DRE™ cells constructed with a proprietary process for producing stably-transfected cell lines. 1A2-DRE™ cells harbor the human AhR gene and a luciferase reporter gene linked to the human CYP1A2 promoter and 3 copies of the dioxin response element (DRE) enhancer. The 1A2-DRE™ cells included in the assay kit remain highly viable upon thawing, and can be immediately dispensed into 384-well plates. There is no need for intermediate spin-and-wash steps. However, determining viability and cell titer is recommended. A list of references describing the use of Puracyp's 1A2-DRE™ cells and other stable cell lines is given in this manual.

Puracyp's *Human AhR Activation Assay System* also includes CellTiter-Fluor™, a cell viability detection reagent, and ONE-Glo™, a luciferase detection reagent, from Promega Corporation. Since the luciferase reporter gene is stably integrated into Puracyp's 1A2-DRE™ cells, the assay gives extremely low background, high sensitivity, and a broad linear dynamic range typical of bio-luminescence reporter gene technology. Further details on the use of CellTiter-Fluor™, ONE-Glo™ and the P450-Glo™ CYP1A2 Assay with Luciferin-IPA can be found at www.promega.com.

In a typical assay, 1A2-DRE™ cells are first dispensed into the wells of the assay plate, and then placed in a CO₂ incubator at 37°C to equilibrate overnight. The following day, the cells are treated with user's test compounds and the appropriate positive control. Since the 1A2-DRE™ cells included with the kit are non-proliferative, test treatment should take place within 24 h of plate seeding. Once treated, the cells are returned to the CO₂ incubator at 37°C for 48 h. The dosing medium is then discarded, cell viability is assessed fluorimetrically with CellTiter-Fluor™, and luciferase activity then measured using ONE-Glo™. The luminescence light intensity is directly proportional to the extent of AhR activation and accompanying gene transcription in the 1A2-DRE™ cells.

II. ASSAY KIT COMPONENTS & STORAGE CONDITIONS

Puracyp's *Human AhR Activation Assay System* (Product 1A2-DRE™-384-001 and 1A2-DRE™-384-002) contains materials to perform reporter assays in a 384 well plate format. The kits are constructed so that 32 reporter assays can be performed in triplicate. Individual aliquots of 1A2-DRE™ cells, media and detection reagents are intended for a single-use. Once 1A2-DRE™ cells have been thawed, they can neither be refrozen nor cultured for future use due to the utilization of a cell-arrest agent during cellular preparation. Therefore, if an entire 384-well plate is not seeded, the remaining cells should be discarded.

Assay kits are shipped on dry ice and the 1A2-DRE cells are shipped in a liquid nitrogen dry shipper. **If the 1A2-DRE™ cells will not be used immediately, they require storage in liquid nitrogen.** The other kit components can be stored at -20° C for up to 90 days. Individual expiration dates are provided with each kit.

KIT COMPONENT	AMOUNT	STORAGE TEMPERATURE
Tube A – 1A2-DRE™ Cells	6 million x 1 vial	Liquid Nitrogen
Tube B - Positive Control (20 mM)	1 x 10 µl	-20° C
Tube C - Culture Media	1 x 10 mL	-20° C
Tube D - Dosing Media	1 x 35 mL	-20° C
Tube E –CTF Buffer	1 x 10 mL	-20° C
Tube F - ONE-Glo™ Assay Buffer	1 x 10 mL	-20° C
Tube G - ONE-Glo™ Assay Substrate, Lyophilized	1 vial	-20° C
Tube H - P450-Glo™ Buffer	1x 10 ml	-20° C
Tube I - Luciferin Detection Reagent, Lyophilized	1 vial	-20° C
Tube J - CellTiter-Fluor™	1 x 5 µl	-20° C
Tube K - Luciferin-IPA	1 vial + 1 vial	-20° C
384-Well Microtiter Plate	1	Ambient
D-CYSTEINE	100 µl	-20° C

III. MATERIALS TO BE SUPPLIED BY USER

The following materials are required by the end-user, and should be available prior to starting the assay procedure.

FOR RECEIPT OF CELLS

- Cell culture-rated hood
- Humidified 5% CO₂/37°C incubator suitable for mammalian cell culture
- 37° C water bath
- Sterile multi-channel media basins or reservoirs
- 70% ethanol mixture
- Multi-channel pipette or liquid handler & sterile tips

FOR DAY 1

- Cell culture-rated hood
- Humidified 5% CO₂/37°C incubator
- 37°C water bath
- Sterile 384 deep well plate (100 µL per well capacity) to make test compound doses (compound dilution plate).
- Sterile media trough or basin
- DMSO or other solvent for use as a test compound diluent and as the negative control
- Multi-channel pipette or liquid handler & sterile tips

FOR DAY 3 (Receptor Activation, 1A2-DRE-384-001 kit)

- Multi-mode microplate reader with capacity to read luminescence and fluorescence. The luminometer portion of the instrument needs to be able to accumulate luminescence RLUs over a 5 sec/well read. Instruments that average the counts per second will produce low counts resulting in low induction and increased well-to-well variability.
- 2 x Sterile Media troughs
- 15 ml sterile conical centrifuge tube
- Multi-channel pipette or liquid handler & sterile tips

FOR DAY 3 (P450 Metabolism and Receptor Activation, 1A2-DRE-384-002 kit)

- White 384-well plate (non-sterile) to read luminescence

PURACYP, INC.

- Multi-mode microplate reader with capacity to read luminescence and fluorescence. The luminometer portion of the instrument needs to be able to accumulate luminescence RLUs over a 5 sec/well read. Instruments that average the counts per second will produce low counts resulting in low induction and increased well-to-well variability.
- 3 x Sterile Media troughs
- Multi-channel pipette or liquid handler & sterile tips
- 2 x 15 ml sterile conical centrifuge tube
- Sterile Phosphate buffered saline (PBS)

IV. ASSAY PROCEDURE

NOTE: It is advisable to review the following section before proceeding with the assay

Puracyp's *Human AhR Activation Assay* incorporates one overnight and one 48 h incubation. *Steps 1-11* are performed upon receipt of cells, and require about **30 min** to complete. *Steps 12-21* are performed on Day 1, and need **1.5 - 3.5 h** to complete, depending on the number of dilutions and compounds to be tested. *Steps 22-49* are performed on Day 3, and require **1.5-5 h** to perform.

RECEIPT OF CELLS: ALL STEPS MUST BE PERFORMED USING PROPER ASEPTIC TECHNIQUE

1. Wipe down tissue culture hood with 70% alcohol solution.
2. Remove 384-well plate from kit and place inside tissue culture hood.
3. Place sterile media trough or basin in hood.
4. Prepare multi-channel pipette or liquid handler with sterile tips.
5. Place Tube C from kit directly into a 37°C water bath until media has thawed and warmed to 37°C, and transfer 10 ml into a sterile trough.
6. Place Tube A containing the 1A2-DRE™ cells into a 37°C water bath for 1-2 min, or until cell suspension has thawed.
Do Not Overheat
7. Sterilize outside of Tube A containing the cells with 70% alcohol solution. Using a 2 ml pipette, aspirate the cell mixture up and down twice to mix, then transfer cells to the sterile trough containing 10 ml medium from Tube C.
8. Remove 2 ml of the cell-media mixture, and use it to rinse out Tube A. Transfer contents back to the media trough.
9. Uniformly mix cells with media by pipetting up and down at least 10X with a 10 ml pipette. It is recommended that the cells be counted to ensure there are 6 million viable cells/vial.
10. Using the multi-channel pipette or liquid handler, transfer 25 µl of cell medium suspension from the trough to the individual wells of 384-well plate. If a re-pipettor is not used during the seeding process, ensure that the cells remain suspended in media by agitating the trough between the seeding of each row/column.
11. Place seeded plate into humidified 5% CO₂/37°C incubator overnight.

DAY 1

12. Place Tube B from kit at room temperature.
13. Place Tube D from kit at room temperature, and allow to thaw.
14. Wipe down tissue culture hood with 70% alcohol solution.

THE FOLLOWING STEPS ARE PERFORMED IN A STERILE HOOD

15. Prepare positive control (Tube B) dilutions as described in **Appendix 1**.
16. Prepare Test Compound dilutions as described in **Appendix 2** if triplicate determinations are planned. Prepare the vehicle control (0.1% DMSO) by adding 1 µl of DMSO to 1 ml of medium from Tube D.
17. Remove 384-well plate from the incubator and place into the hood.
18. Prepare the plate for test agent addition by demarcating on the lid those wells that will receive test articles, positive controls, vehicle control, and medium control.
19. Remove the liquid from each well by gently tapping the plate several times upside down on a sterile surface. Ensure that all media is removed but do not disturb the cells.
20. Gently add 25 µl of media containing test agent, positive control or vehicle control to the plate wells. Media addition is performed by gently pipetting the liquid against the well walls rather than directly onto the cells attached to the well bottom.
21. Return the plate to the incubator, and continue to incubate at 37°C for 48 h^A.

^APuracyp's Human AhR Nuclear Receptor Activation Assay is designed to give maximum induction after 1A2-DRE cell treatment with a single dose of BNF for 48 h at 37°C. However, compounds other than BNF may be less stable in culture at 37°C, and may thus require replenishment after 24 h. In those instances, the user should repeat Day 1 steps #12-21 again on Day 2.

DAY 3 Receptor Activation (1A2-DRE-384-001 kit)

22. Allow Tubes E, F, G & J to reach room temperature.
23. Add the contents of Tube F (ONE-Glo™ Assay Buffer) to Tube G (ONE-Glo™ Assay Substrate), cap, and invert the bottle 3X to mix.
24. Transfer 10 ml from Tube E to a sterile 15 ml conical tube, and add 5 µl from Tube J (CellTiter-Fluor™). Mix by inverting tube. Pour into sterile media trough.
25. Remove 384-well plate from the incubator.
26. Remove the liquid from each well by gently tapping the plate several times upside down on a sterile surface. Ensure that all media is removed but do not disturb the cells.
27. Pour contents of 15 ml conical tube (containing CellTiter-Fluor™ reagent) into a sterile media trough. Using a multi-channel pipette or liquid handler, gently add 25 µl of CellTiter-Fluor™ reagent into each well.
28. Place 384-well plate in the incubator for 60 min.

The Following Steps Do Not Require Sterile Conditions

29. Remove 384-well plate from the incubator, briefly allow to cool to ambient temperature, and then measure fluorescence of individual wells with a microplate reader in fluorescence mode using an excitation wavelength of 380-400 nm and an emission wavelength of 505 nm. Read plate at 10 msec/well.
30. Pour ONE-Glo™ Assay reagent (prepared in Step #23) into a media trough, and then add 25 µl of this reagent into each well of the plate.
31. Carefully agitate the plate to mix the reagents contained in the wells.
32. After 5 min, read the luminescence of individual wells using a luminometer set for a 5 sec pre-shake with a 5 sec/well read time. A high gain (sensitivity) setting should be used.

DAY 3 P450 Metabolism and Receptor Activation (1A2-DRE-384-002 kit)

THE FOLLOWING STEPS ARE PERFORMED IN A STERILE HOOD

33. Allow Tubes E, F, G, H, I, J, K and D-cysteine to reach room temperature.
34. Add 6 µl from Tube K (Luciferin-IPA) to 6 ml of sterile phosphate buffered saline (PBS) to a sterile 15 ml conical tube, mix and pour into media trough.
35. Remove 384-well plate from the incubator after 48 h and place into the hood.
36. Remove the liquid from each well by gently tapping the plate several times upside down on a sterile surface. Ensure that all media is removed but do not disturb the cells.
37. Wash cells with 25 µl/well of phosphate buffered saline (PBS). Gently discard PBS in the same manner.
38. Add 50 µl from the media trough containing Luciferin-IPA in PBS to each well.
39. Return plate to incubator for 180 min (3 h) at 37°C.
40. During incubation with Luciferin-IPA, pour the contents of Tube H (P450-Glo™ Buffer) into Tube I (Luciferin Detection Reagent). Mix by inversion and add 100 µl of D-cysteine. Mix by inversion and pour into media trough. Also, prepare a replicate white non-sterile 384 well plate.
41. Following the 3 h incubation, remove 384-well plate from the incubator. Carefully transfer 50 µl from each well of the original plate to the corresponding well of a **White** non-sterile 384-well plate that replicates the format of the original plate. Remove non-sterile plate from hood.
42. Following transfer of Luciferin-IPA substrate to replicate plate and removal from hood, in the hood transfer 10 ml from Tube E to a sterile 15 ml conical tube, and then add 5 µl from Tube J (CellTiter-Fluor™). Mix by inversion. Pour into media trough.
43. Using a multi-channel pipette or liquid handler, gently add 25 µl of CellTiter-Fluor™ reagent into each well of the original 384-well plate containing the cells. Return plate to the incubator for 60 min.


The Following Steps Do Not Require Sterile Conditions

44. Add 50 µl of P450-Glo™ Buffer/Luciferin Detection Reagent containing the D- cysteine (prepared in step # 39) to each well of the replicate plate, and incubate at room temperature for 20 min.
45. After the 20 min incubation with Luciferin Detection Reagent, measure the luminescence of the white non-sterile 384-well plate with the luminometer set for a 1-5 sec/well read time. A fairly high gain (sensitivity) setting should be used.
46. Add the contents of Tube F (ONE-Glo™ Assay Buffer) to Tube G (ONE-Glo™ Assay Substrate), cap, and mix by inversion.
47. Following the 60 min incubation with CellTiter-Fluor, remove the original 384-well plate from the incubator, allow to cool to room temperature, and then measure fluorescence of individual wells with a microplate reader in fluorescence mode using an excitation wavelength of 380-400 nm and an emission wavelength of 505 nm.
48. Pour ONE-Glo™ Assay reagent (prepared in Step #45) into a media trough, and add 25 µl of the reagent into each well of the plate.
49. Carefully agitate the plate to mix the reagents contained in the wells.
50. After 5 min, read the luminescence of the individual wells with the luminometer set for a 5 sec pre-shake with a 5 sec/well read time. RLUs should be cumulative over the 5 sec/well read time. A relatively high gain setting should be used.

QUANTITATION OF AhR RECEPTOR ACTIVATION


1. Determine the average Relative Luminescence Units (RLU) of the three replicates for each test compound at each dosage. In addition, determine the average Relative Fluorescence Units (RFU) of the three replicates for each test compound at each dosage. RFU values should range between 5000-9000. If the values exceed 9000 RFU, adjust sensitivity or read time/well of the fluorimeter.
2. Determine the mean RLU and RFU for the 0.1% DMSO vehicle control replicates. RLU values for DMSO or media should range 1000-6000. If values are less than 1000, increase the sensitivity of the luminescence readout and ensure that the luminometer is accumulating counts over the 5 sec/well read and providing a readout per 5 sec, not as an average expressed as 1 sec/well.
3. Normalize the luciferase activity for cell viability by dividing the average RLU by the average RFU for each test compound at each dosage as well as for the vehicle control.
4. AhR receptor activation at the individual test compound doses is calculated by dividing the normalized luciferase activity (RLU/RFU) for the test compound doses by that of the normalized DMSO vehicle control. The final data is expressed as fold activation relative to the vehicle control. The use of 5 or more doses of test compound and positive control allows for the derivation of EC₅₀ and E_{MAX} values from nonlinear regression analysis of the log dose-response curves. Graphpad Prism (Graphpad Software, La Jolla, CA) and SigmaPlot (Systat Software, San Jose, CA) are among the software programs with built-in equations for deriving these AhR activation kinetic parameters.

- Test compound values should be compared to those obtained for the positive (BNF) control. An example of a typical AhR activation dose-response curve generated with 6 concentrations of BNF is shown below.



Quantitation of P450 Substrate Metabolism

- Receptor activation by test compounds, positive controls, and negative (vehicle) controls are determined as described above.
- To assess whether the test compounds also increased P450 metabolic activity, determine the average RLU of the three Luciferin-IPA replicates for each test compound at each dosage in the replicate 384-well plates. In addition, determine the average RLU of the three replicates for the DMSO (vehicle) controls.
- Normalize the P450-Glo™ activity for cell viability (determined on the original plate) by dividing the average RLU by the average viability (RFU) for each test compound at each dosage as well as for the vehicle control.
- Fold induction by the individual doses of test compound is calculated by dividing the normalized P450-Glo™ (Luciferin-IPA) luciferase activity (RLU/RFU) for the test compound doses by that of the normalized DMSO vehicle control. The results should be expressed as fold increase (induction) above DMSO-treated cells.



A typical dose-response curve for CYP1A2 metabolism generated in 1A2-DRE™ cells treated with 6 concentrations of BNF. P450 1A2 metabolism of Luciferin-IPA was monitored in a multiplex fashion. As expected, metabolic activity was enhanced by BNF.

NOTE: It is not uncommon to obtain extensive AhR activation but negligible induction of P450 substrate metabolism. This happens in cases where the AhR activating compound inhibits the P450 enzyme that metabolizes the P450 Glo™ substrate. The capacity to multiplex Puracyp's Human AhR Activation Assay System allows one to identify such molecules as well as those that exhibit cellular toxicity.

TROUBLESHOOTING GUIDE

SYMPTOM	POSSIBLE CAUSE	RESOLUTION
High Well-to-Well Variation	Cells Not Evenly Dispersed Among Wells	Mix cells thoroughly with medium before seeding. To facilitate even plating, ensure the cells in Tube A are pipetted up/down at least twice prior to transfer to culture medium. Upon transfer, mix cells with culture medium by pipetting up/down 10 times.
Weak Activation with Potent Positive Control	Inadequate cell number	Ensure that there are 6 million viable cells per vial. Each well of a 384 well plate should receive 60,000 cells/well. To ensure that the cells arrived in good condition following shipping, it is recommended that the cells be counted and viability checked prior to seeding in the 384 well plate.
	Luminometer Settings	The luminometer used should be one that can be set to a high level of sensitivity. Ensure that your instrument is set to 1 sec/well read time and is set on the highest sensitivity (gain) possible.

Weak Activation with Test Compounds	Poor Test Compound Solubility	Test compounds dissolved in DMSO and other solvents precipitate out of solution when added to culture media. This often occurs at higher concentrations. Weak activation stemming from poor solubility would be indicated by: a) a peak activation response occurring midway in the dose-response curve, followed by decreasing responses at higher concentrations and; b) no change in cell viability throughout the entire concentration curve.
	Effects on Cell Viability	Test compound cytotoxicity can result in weak AhR activation. Cell viability should be assessed using CellTiter-Fluor™ reagent, and the fold AhR activation normalized to the viable cell number for a given test compound. A decline in receptor activation and cell viability over the concentration range examined would indicate that the test compound is toxic to the 1A2-DRE™ cells.
False Positives	Borderline Activation by Non-AHR Ligands	The low levels of AhR activation observed with certain compounds may not be indicative of “false positives”. Cut-off values, commonly expressed as % of BNF, should be established to differentiate negative, weak, moderate and potent AhR activators. For example, compounds giving activation < 15% of that observed with 10 µM BNF would be considered negative. Agents giving 15 - 40% of the response observed with 10 µM BNF would be considered weak activators while those eliciting 41 - 69% of the BNF response would be moderate activators. Only those compounds giving ≥ 70% of the response noted with 10 µM BNF would be considered strong or potent AhR activators.

Potent AHR Activation But Weak Induction of CYP1A2 Metabolism	Test Compound is an Irreversible (Time-Dependent) CYP1A2 Inhibitor	Certain agents elicit potent activation of AhR together with marked induction of CYP1A2 enzyme levels but fail to give a corresponding increase in CYP1A2-dependent metabolism. This well-documented phenomenon stems from the irreversible, time-dependent inhibition of CYP1A2 by such compounds during their metabolism by the same enzyme.
---	--	--

For any additional questions and/or problems with Puracyp's *Human AhR Activation Assay System*, please contact us by phone at 760-929-9508 or by email at support@puracyp.com.

V. LIMITED USE DISCLOSURES

Products commercialized by PURACYP, Inc. are intended for RESEARCH PURPOSES ONLY, and not for diagnostic or therapeutic use in humans. Deviations from the protocol(s) described herein will void product warranties, either expressed or implied. In addition, Puracyp will not indemnify utilization of the cells contained in this assay kit.

BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE STATEMENT. If the researcher is not willing to accept the conditions of this limited use statement, and the product is unused, Puracyp will accept return of the unused product and provide the researcher with a full refund. Researchers may use this product for research use only, no commercial use is allowed. Commercial Use means any and all uses of this product and derivatives by a party for monetary or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research. Researchers shall have no right to modify or otherwise create variations of the nucleotide sequence of the luciferase gene except that Researchers may: (1) create fused gene sequences provided that the coding sequence of the resulting luciferase gene has no more than four deoxynucleotides missing at the affected terminus compared to the intact luciferase gene sequence, and (2) insert and remove nucleic acid sequences in splicing research predicated on the inactivation or reconstitution of the luminescence of the encoded luciferase. No other use or transfer of this product or derivatives is authorized without the prior express written consent of Promega. In addition, Researchers must either: (1) use luminescent assay reagents purchased from Promega Corporation for all determinations of luminescence activity of this product and its derivatives; or (2) contact Promega to obtain a license for use of the product and its derivatives. Researchers may transfer derivatives to others for research use provided that at the time of transfer a copy of this label license is given to the recipients and recipients agree to be bound by the terms of this label license. With respect to any uses outside this label license, including any diagnostic, therapeutic or prophylactic uses, please contact Promega for supply and licensing information. PROMEGA NOR PURACYP MAKE ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING FOR MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THE PRODUCT. The terms of this agreement shall be governed under the laws of the State of Wisconsin, USA. The above license relates to Promega patents and/or patent applications on improvements to the luciferase gene.

PURACYP, INC.

1A2-DRE™ cells are covered by U.S. Pat. No. 5,670,356, European Pat. No. 1341808 and other patents pending owned by Promega Corporation and licensed by Puracyp.

ONE-Glo™ and CellTiter-Fluor™ are subject to patents pending by Promega Corporation.

P450-Glo™ CYP1A2 Assay with Luciferin-IPA is covered by U.S. Pat. Nos. 6,602,677 and 7,724,584, European Pat. No. 1131441 and other patents pending owned by Promega Corporation.

The method of recombinant expression of Coleoptera luciferase is covered by U.S. Pat. Nos. 5,583,024, 5,674,713 and 5,700,673.

Additional information on ONE-Glo™, CellTiter-Fluor™ and the P450-Glo™ CYP1A2 Assay with Luciferin-IPA can be found at www.promega.com.

DISCLAIMER

PURACYP, INC. MAKES NO CLAIMS OR WARRANTIES, EITHER IMPLIED OR EXPRESSED, AS TO THE PHYSIOLOGICAL EFFECT OF ANY COMPOUND IN VIVO ASSAYED WITH OUR TECHNOLOGY. PURACYP DOES NOT WARRANT THAT SIMILAR EFFECTS WILL OCCUR IN WHOLE ORGANISMS (*IN VIVO*).

COMPOUNDS THAT ARE TOXIC OR INHIBIT CELL CYCLE EVENTS MAY NOT EXHIBIT INDUCTION IN PURACYP'S CELL LINES BUT RECEPTOR ACTIVATION MAY BE OBSERVED IF A VIABILITY ASSAY IS PERFORMED AND RESULTS NORMALIZED TO THAT ASSAY IN THE CASE OF CYTOTOXICITY.


IF THE ABOVE TERMS ARE NOT ACCEPTABLE, PROMPTLY CONTACT PURACYP. FAILURE TO PROMPTLY CONTACT PURACYP IN WRITING WITHIN TWO DAYS OF DELIVERY CONSTITUTES ACCEPTANCE OF THE ABOVE TERMS. DEVIATIONS FROM THE ABOVE PROTOCOLS WILL VOID WARRANTIES.

VI. REFERENCES

- Raucy JL, Warfe L, Yueh M-F, Allen SW: A cell-based reporter gene assay for determining induction of CYP3A4 in a high volume system. *J Pharmacol Exp Ther* 303: 412-423, 2002.
- Yueh M-F, Kawahara M, Raucy JL: High-volume bioassays to assess CYP3A4-mediated drug interactions: Induction and inhibition in a single cell line. *Drug Metab Disp* 33:38-48, 2005
- Yueh M-F, Kawahara M, Raucy JL: Cell-based high-throughput bioassays to assess induction and inhibition of CYP1A enzymes. *Toxicology In Vitro*. 19:275-287, 2005.
- Trubetskoy O, Marks B, Zielinski T, Yueh M-F, Raucy JL: A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line. *AAPS Journal* 07(01): E6-E13, 2005.
- Sinz MW, Devin Pray, Raucy JL: The utility of stable cell lines to assess species differences in PXR transactivation. *Drug Metab Lett* 1: 147-152, 2007.
- Lipp E: Tackling Drug-interaction issues early on. *Genetic Engineering & Biotechnology News*, June 15: 14-20, 2008.
- Lamb JG, Hathaway LB, Munger MA, Raucy JL, Franklin MR: Nano-silver particle effects on drug metabolism. *Drug Metab Disp* 38:2246-2251, 2010.
- Raucy JL, Lasker JM: Current *in vitro* high throughput screening approaches to assess nuclear receptor activation. *Curr Drug Metab* 11:806-814, 2010.
- Shukla, SJ, Sakamuru, S, Huang, R, Moeller, TA, Shinn, P, VanLeer, D, Auld, DS, Austin, CP and Menghang, X. Identification of clinically used drugs that activate pregnane X receptors. *Drug Metab Disp* 39: 151-159, 2011.
- Fahmi, O., Raucy, J. L., Ponce, E, Hassanali, S. and Lasker, J. M. The Utility of DPX Cells for predicting CYP3A4 induction-mediated drug-drug interactions and associated structure activity relationships. *Drug Metab. Disp.*40: 2204-2211, 2012.
- Raucy, J.L. and Lasker, J. M. Cell-based systems to assess nuclear receptor activation and their use in drug development. *Drug Metab. Rev.* 45:101-109, 2013.
- Raucy, J. L. Human Pregnane X Receptor (hPXR) Activation Assay in Stable Cell Lines. In Optimization in Drug Discovery: In Vitro Methods, Methods in Pharmacology and Toxicology. Ed. Caldwell, G. W. and Yan Zhengyin, pp.171-193, Springer Science, NY. 2014.

APPENDIX 1 FOR DRE-1A2-384-001 AND DRE-1A2-384-002


Dilution Scheme for Dosing Positive Control



All test compound dilutions are made with neat DMSO, after which the individual solutions are added to dosing medium at a ratio of 1:100.

APPENDIX 2 FOR DRE-1A2-384-001 AND DRE-1A2-384-002

Dilution Scheme for Dosing Media-Insoluble Test Compounds



All test compound dilutions are made with neat DMSO, after which the individual solutions are added to dosing medium at a ratio of 1:100.

APPENDIX 3: QUICK REFERENCE CARD
HUMAN AhR NUCLEAR RECEPTOR ACTIVATION ASSAY WITH ASSESSMENT
OF CELL VIABILITY IN A 96-WELL FORMAT (1A2-DRE-96-001)

USE STERILE TECHNIQUE FOR STEPS 1-17

KIT RECEIPT DAY

1. Thaw Tube C by warming in a 37°C water bath, and transfer 10 ml into a media trough.
2. Place Tube A containing 1A2-DRE cells in a 37°C water bath until cell suspension has thawed.
3. Pipette cells into the media trough containing 10 ml of Reagent C, and mix by pipetting up-and-down 10 times. Count cells and determine viability.
4. Transfer 100 µl of cell mixture into plate wells, keeping cells suspended while pipetting.
5. Place seeded plate into a humidified CO₂ incubator at 37°C overnight.

DAY 1

6. Thaw Tube D in a 37°C water bath.
7. Allow Tube B to thaw at room temperature.
8. Prepare series of Test Compound and Positive Control dilutions in DMSO (see Appendices 1 & 2) followed by 1:1000 dilutions in dosing medium (Tube D).
9. Remove plate from the incubator, and carefully aspirate and discard the media from each well. Do not disturb the cells during the aspiration process.
10. Transfer 100 µl of each test compound concentration into pre-marked wells. Do the same with positive controls and vehicle controls.
11. Return plate to the incubator for a 48 h exposure to the treatments.

DAY 3

12. Thaw Tube J containing CellTiter-Fluor™.
13. Thaw Tube E and transfer 10 ml to a sterile 15 ml centrifuge tube. Add 5 µl of CellTiter-Fluor™. Mix by inversion and pour into media trough.
14. Thaw Tube F containing ONE-Glo™ Luciferase Assay Buffer, and add to Tube G containing ONE-Glo™ Assay Substrate; mix vial several times by inversion. Pour into media trough.
15. Remove plate from the incubator, and carefully aspirate and discard all dosing medium containing test compounds, positive controls, and negative (vehicle) controls.
16. Add 100 µl of Tube E containing the CellTiter-Fluor™ reagent (prepared in Step 13) to each well.
17. Return plate to the incubator for 60 min.
18. After incubation, measure fluorescence of individual wells with a multi-mode microplate reader^A set for fluorescence using an excitation wavelength of 380-400 nm and an emission wavelength of 505 nm.
19. Remove plate from instrument, and add 100 µl of ONE-Glo™ Assay reagent to each well. Agitate plate to mix, and incubate for 5 min at room temperature.
20. Measure luminescence of individual wells with the multi-mode reader set for a 5 sec pre-shake and a 5 sec/well read. A high instrument gain (sensitivity) setting should be used.
21. Receptor activation is calculated according to the method given in the *Complete Protocol*.

CellTiterFluor™ and ONE-Glo™ are trademarks of the Promega Corporation.

^AA stand-alone fluorimeter and luminometer can also be used

APPENDIX 4: QUICK REFERENCE CARD
HUMAN AhR NUCLEAR RECEPTOR ACTIVATION ASSAY WITH CELL VIABILITY AND CYP1A2
SUBSTRATE METABOLISM IN A 96-WELL FORMAT (1A2-DRE-96-002)

USE STERILE TECHNIQUE FOR STEPS 1-20

KIT RECEIPT DAY

1. Thaw Tube C by warming in a 37°C water bath, and transfer 10 ml into a media trough.
2. Place Tube A containing 1A2-DRE cells in a 37°C water bath until cell suspension has thawed.
3. Pipette cells into the media trough containing 10 ml of Reagent C, and mix by pipetting up-and-down 10 times. Count cells and determine viability.
4. Transfer 100 µl of cell mixture into plate wells, keeping cells suspended while pipetting.
5. Place seeded plate into a humidified CO₂ incubator at 37°C overnight.

DAY 1

6. Thaw Tube D in a 37°C water bath.
7. Allow Tube B to thaw at room temperature.
8. Prepare series of Test Compound and Positive Control dilutions in DMSO followed by 1:1000 dilutions in Dosing Medium (Tube D) (see Appendices 1 & 2).
9. Remove plate from the incubator, and carefully aspirate and discard the medium from each well. Do not disturb the cells during the aspiration process.
10. Transfer 100 µl of each test compound concentration into pre-marked wells. Do the same with positive controls and vehicle controls.
11. Return plate to incubator for 48 h^A

DAY 3

12. Thaw Tubes J and K containing CellTiter-Fluor™ and Luciferin-IPA, respectively.
13. Allow Tubes D, E, F, G, H, I, and D-Cysteine to reach room temperature.
14. Add 6 µl of Tube K to 6 ml of sterile phosphate buffered saline (PBS). Mix by inversion. Pour into media trough.
15. Remove 96-well plate from incubator and carefully remove media from wells and discard.
16. Add 50 µl of the Luciferin-IPA reagent to each well. Return plate to incubator for 180 min.
17. During the incubation, pour Tube H (P450-Glo buffer) into Tube I (Luciferin Detection Reagent) and mix by inversion. Add 100 µl of D-cysteine and mix. Pour into media trough.
18. After 3 h incubation, remove 96-well plate from the incubator, and transfer 50 µl from each well to the corresponding well of a non-sterile white 96-well plate that replicates the format of the original plate.
19. After transfer of P450-Glo™ to replicate plate, transfer 10 ml of Tube E to a 15 ml sterile conical tube, add 5 µl of CellTiter-Fluor™ (Tube J), and mix by inversion. Pour into media trough.
20. Using a multi-channel pipette, gently add 100 µl of CellTiter-Fluor™ reagent into each well of the original 96-well plate containing the cells. Return plate to the incubator for 60 min.

21. Add 50 μ l of Luciferin Detection Reagent/P450-Glo Buffer containing the D-cysteine (prepared in step # 17) to each well of the replicate micro-titer plate, agitate the plate, and incubate at room temperature for 20 min.
22. After 20 min incubation with Luciferin Detection Reagent, determine luminescence of the wells of the non-sterile white 96-well plate with the luminometer set for a 1-5 sec/well read time. A relatively high gain setting should be used.
23. Add Tube F containing ONE-Glo™ Luciferase Assay Buffer to Tube G containing ONE-Glo™ Assay Substrate; mix by inversion. Pour into media trough.
24. After 60 min incubation at 37°C (see step #20), remove original 96-well plate from incubator and measure fluorescence of individual wells with multi-mode microplate reader^B set to the fluorescence mode using an excitation wavelength of 380-400 nm and an emission wavelength of 505 nm.
25. Remove plate from instrument, and add 100 μ l of ONE-Glo™ Assay reagent to each well. Agitate plate to mix, and incubate for 5 min at room temperature.
26. Measure luminescence of individual wells with the multi-mode reader set for a 5 sec pre-shake and a 5 sec/well read. A high instrument gain (sensitivity) setting should be used.
27. Receptor activation is calculated according to the method given in the Complete Protocol.

CellTiterFluor™ and ONE-Glo™ are trademarks of the Promega Corporation.

^APuracyp's Human AhR Nuclear Receptor Activation Assay is designed to give maximum induction upon treatment of 1A2-DRE cells for 48 h at 37°C with a single dose of BNF. However, compounds other than BNF may be less stable in culture at 37°C, and thus may not function as AhR ligands for the entire treatment period. In those instances, the user may want to perform two 24 h treatments, which will require that Day 1 Steps #8-11 are repeated on Day 2.

^BA stand-alone fluorimeter and luminometer can also be used.